Biotech Stocks At 52-Week Highs - MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO
MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
How this was made
The 30-second read
Why it matters
The article aggregates price moves without presenting new fundamental information, limiting actionable insight.
Market read
Highlights short‑term bullish sentiment in biotech but offers limited trading signals.
What to watch
Potential upcoming regulatory reviews or trial setbacks could reverse the momentum.
Background
A daily roundup highlighting biotech stocks that reached 52‑week highs on September 17, 2026.
Ticker impact
Shares surged 36% to a 52‑week high of $3.89 on Thursday.
Potential pull‑back after the move; watch for volume fade.
No concrete new data released; price action appears momentum‑driven.
Stock rose over 9% to a 52‑week high of $13.18 after Phase 2 results for ABCL635.
May stabilize; monitor upcoming conference presentation.
Result details were already known; move reflects market reaction.
Shares climbed 10% to $42.22, hitting a 52‑week high.
Likely to face short‑term resistance near the high.
No new trial data disclosed; price rise is momentum‑based.
Shares reached a 52‑week high of $109.83 after reporting Q1 results.
Potential consolidation; watch for follow‑on guidance.
Earnings were already released earlier in the day; move is a reaction.
Shares rose over 5% to $19.89, a 52‑week high, after Medicare coverage news.
May test resistance at the high; watch volume.
Coverage news was announced earlier; price action reflects immediate market response.
Market effects
Biotech sector shows broad strength as multiple names hit 52‑week highs.
U.S. biotech equities gain, modest lift to Nasdaq biotech indices.
Limited; primarily U.S. market participants affected.
Counterpoint
The rally may be over‑extended without fresh data; a pull‑back could present short opportunities.
Key entities
- companyMediciNova Inc.
Biopharma developing small‑molecule therapeutics.
- companyAbCellera Biologics Inc.
Antibody discovery platform.
- companyParabilis Medicines Inc.
Helical peptide therapeutics developer.
- companyHaemonetics Corporation
Medical technology and plasma collection.
- companyNeoGenomics Inc.
Diagnostics and cancer testing.
